Cat. No. 3314
Chemical Name: 4-(2,3-Dihydro-1,4-benzodioxin-6-yl
Biological ActivityCompetitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50 = 500 nM) and prevents JNK substrate phosphorylation. Blocks JNK-dependent Con A-induced liver damage and restores insulin sensitivity in a mouse model of type II diabetes.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Flight (2008) Getting rid of JNK. Nat.Rev.Drug Disc. 7 975.
Haas and Writer (2008) Block JNK at the dock. SCiBX 1 1.
Stebbins et al (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc.Natl.Acad.Sci.USA 105 16809.
If you know of a relevant citation for this product please let us know.
Keywords: BI 78D3, supplier, Selective, competitive, JNK, inhibitors, MAPK, Signaling, Signalling, c-Jun, N-Terminal, Kinases, SAPKs, Stress-Activated, Protein, Mitogen-Activated, p38, BI78D3
Find multiple products by catalog number
New Products in this Area
p38 MAPK inhibitorETP 45835 dihydrochloride
Mnk1 and Mnk2 inhibitorAL 8697
Potent and selective p38α inhibitorDBM 1285 dihydrochloride
p38 MAPK inhibitor; anti-inflammatorySR 3576
Highly potent and selective JNK3 inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.